How competition nearly killed Alzheimer’s research
Repeat failures put the brakes on research until the pharma industry regrouped in a new, non-competitive, way.
Site Search
Site Search
Displaying results 301 - 310 of 893
Focus on: Alzheimer's disease
Alzheimer’s is a scientific failure. It's an area of research suited to a public private partnership because it offers companies a chance to pool the lessons they've learned, mistakes they've made, and data they've compiled from years of unsuccessful attempts to develop ...
Genetically engineered antibodies cut infection rates in a trial. Could they wean us off antibiotics?
Researchers’ hopes are raised after a trial using monoclonal antibodies to prevent pneumonia in ventilated intensive care patients gets good results
IMI research gets cited at double the global average rate
Report shows rise in performance, with IMI research cited 60% more than EU average and twice as much as the rest of the world.
Can real world data replicate a clinical trial? EHDEN study suggests yes
IMI’s EHDEN project dramatically demonstrated the power of using clinical data in research by replicating, during a five-day ‘study-a-thon’, the results of a systematic review covering 20 years of research, and a multi-year clinical trial.
New IMI project 3TR to advance personalised treatments for immune diseases
3TR hopes to unravel the mystery of why treatments don't work in some patients.
Technology, not instinct, should guide antibiotic prescribing. A Q&A with Herman Goossens
Quick tests for bacterial infections are out there, but insurers won’t cover them and doctors are reluctant to use them.
Trials@Home project brings clinical trials to the patient
In the future, patients could take part in clinical trials from the comfort of their own home, avoiding the inconvenience of regular clinic visits.
How can we make clinical trials more kid-friendly?
IMI-funded researchers are inviting children and young people to help decide how clinical trials with child participants should be run.
